Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022 ...Middle East

New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study Other data presented demonstrate the long-term safety profile of STELARA® (ustekinumab) in bio-naïve and...

Hence then, the article about janssen presents study results showing clinical efficacy for tremfya guselkumab and long term safety profile for stelara ustekinumab for patients living with inflammatory bowel disease at digestive disease week 2022 was published today ( Tuesday 24/05/2022 - 11:24 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022 )

Also on site :

• 2010s Rock Band Announces Tour for 10th Anniversary of Debut Album
• Nuclear neighbors and a two‑front threat: Why India needs a rocket force
• Greenland hit by power outage, strong winds in wake of US tensions easing